Free Trial

Alkermes (ALKS) Stock Forecast & Price Target

$24.39
+0.29 (+1.20%)
(As of 04:16 PM ET)

Alkermes - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Consensus Price Target

$36.50
49.65% Upside
High Forecast$50.00
Average Forecast$36.50
Low Forecast$25.00
TypeCurrent Forecast
7/2/23 to 7/1/24
1 Month Ago
6/2/23 to 6/1/24
3 Months Ago
4/3/23 to 4/2/24
1 Year Ago
7/2/22 to 7/2/23
Consensus Rating
Moderate Buy
Moderate Buy
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
7 Buy rating(s)
6 Buy rating(s)
5 Buy rating(s)
2 Buy rating(s)
Hold
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
3 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$36.50$36.78$33.14$33.33
Forecasted Upside49.65% Upside38.55% Upside19.34% Upside20.81% Upside

ALKS Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ALKS Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Alkermes Stock vs. The Competition

TypeAlkermesMedical CompaniesS&P 500
Consensus Rating Score
2.55
2.70
2.50
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside49.65% Upside817.10% Upside12.52% Upside
News Sentiment RatingPositive News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
6/17/2024TD Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Thome
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$34.00+38.78%
6/4/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral ➝ Neutral$35.00 ➝ $35.00+45.50%
5/23/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$43.00 ➝ $48.00+97.77%
4/9/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$42.00 ➝ $50.00+87.62%
4/1/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOverweight ➝ Overweight$39.00+43.91%
3/19/2024Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$37.00+34.40%
Buy this small stock before coming AI Tidal Wave (Ad)

The internet generated more wealth than any other innovation in history - creating hundreds of thousands of new millionaires in America alone. Now A.I. could do the same. But if you're buying Microsoft or NVIDIA to profit - you're missing the big picture.

Get the name and ticker symbol for free - just click here.
2/20/2024UBS Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeNeutral ➝ Sell$25.00-22.31%
1/2/2024Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$27.00 ➝ $29.00+0.55%
11/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingNeutral$33.00+36.14%
10/26/2023Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetBuy ➝ Buy$37.00 ➝ $35.00+43.09%
10/24/2023Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeIn-Line ➝ Outperform
2/16/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$30.00+4.71%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Monday at 04:44 PM ET.

ALKS Forecast - Frequently Asked Questions

What is Alkermes's stock forecast and purchase recommendation?

According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Alkermes is $36.50, with a high forecast of $50.00 and a low forecast of $25.00. The consensus rating for Alkermes stock is Moderate Buy based on the current 1 sell rating, 3 hold ratings and 7 buy ratings for ALKS. Learn more on ALKS's analyst rating history.

Do Wall Street analysts like Alkermes more than its competitors?

Analysts like Alkermes less than other "medical" companies. The consensus rating score for Alkermes is 2.55 while the average consensus rating score for "medical" companies is 2.70. Learn more on how ALKS compares to other companies.

Does Alkermes's stock price have much upside?

According to analysts, Alkermes's stock has a predicted upside of 38.35% based on their 12-month stock forecasts.

What analysts cover Alkermes?

Alkermes has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, and TD Cowen in the past 90 days.


This page (NASDAQ:ALKS) was last updated on 7/1/2024 by MarketBeat.com Staff

From Our Partners